Slide 1: Q2/H1 2025 Results Presentation
Q2/H1 2025 Results Presentation Dietmar Siemssen Dr. Bernd Metzner
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: Q2 2025 Overview
Q2 2025 Overview Dietmar Siemssen (CEO)
Slide 4: Q2 2025 – Gerresheimer Group Plays in a New League
Q2 2025 – Gerresheimer Group Plays in a New League Leap forward in reported revenue and adjusted EBITDA Growth Revenues Adj. EBITDA (in EURm) (in EURm) Growth yoy: Growth yoy: +19.6% +10.8% 601 119 107 502 Q2 2024 Q2 2025 Q2 2024 Q2 2025 4 10-Jul-2025 Gerresheimer AG - Q2 2025 Results Presentation
Slide 5: Unforeseen Headwinds Weighing on Growth & Profitability
Unforeseen Headwinds Weighing on Growth & Profitability Q2 2025: Top Line & Order Book supporting stronger H2 YoY growth − Shifted revenues for Syringes came through − Weakness in cosmetics & Reported Organic as expected primary packaging for Revenue − Growth in vials, stronger oral liquids +19.6% 1
Slide 6: Soft H1 weighing on 2025; H2 and Long-Term Growth Prospects Intact
Soft H1 weighing on 2025; H2 and Long-Term Growth Prospects Intact Stronger H2, but not fully Actions taken compensating slow H1 growth Long-term growth prospects intact considering H1 development dynamic ▪ Resumption of full production in ▪ 2025 guidance adjusted ▪ Growing share of systems and Morg
Slide 7: Contributions to Profitable Growth in H2/2025
Contributions to Profitable Growth in H2/2025 Return to operations, ramp-ups and continuous shift to high value products Lohr | Moulded Glass Pharma, F&B Morganton | Vials Skopje | Medical devices Peachtree | Medical devices Bünde | Syringes Querétaro | RTF vials 7 10-Jul-2025 Gerresheimer AG - Q2 2
Slide 8: Lohr: The world's first Oxy-Hybrid Furnace of this size
Lohr: The world's first Oxy-Hybrid Furnace of this size Operates with up to 50% electricity | 70% from renewable sources, targeting 100% by 2030 LCE Oxy-Flex hybrid cross-heated furnace Highly efficient, emission- & energy-optimized melting technology 50 % - Higher use of electricity (50% electricit
Slide 9: Peachtree: Expansion for Medical Devices
Peachtree: Expansion for Medical Devices Two-stage expansion will triple output until 2028 | One of Gx sites with GLP-1 business High precision plastics injection molding and assembling ▪ 18,000 m² expansion in two stages ▪ Line ramp-up of first expansion stage started in Q2, line ramp-up of second
Slide 10: Querétaro: Expansion for Syringes and EZ-fill Smart
Querétaro: Expansion for Syringes and EZ-fill Smart® State-of-the-art systems for glass forming | One of Gx sites with GLP-1 business Innovative EZ-fill Smart® platform for RTF injection vials & cartridges ▪ 7,500m² new factory building for RTF syringes ▪ Glass forming and needle mounting ▪ Clean ro
Slide 11: Financial Performance Q2 2025
Financial Performance Q2 2025 Dr. Bernd Metzner (CFO)
Slide 12: Q2 2025 – Growth to Accelerate in H2
Q2 2025 – Growth to Accelerate in H2 Operational view on KPIs in Q2 2025 2024 figures Revenues1 on pro forma basis Adj. EBITDA1 Adj. EPS (in EURm) (in EURm) (in EUR) Organic growth yoy: Organic growth yoy: Currency-neutral growth yoy: 1.9% -4.1% -27.9% 125 1,24 596 601 119 0,90 Q2 2024 Q2 2025 Q2 20
Slide 13: Q2 2025 – Growth Resumed
Q2 2025 – Growth Resumed Operational view on KPIs in Q2 2025 by division Organic yoy In EURm & margin Revenues1 Adj. EBITDA1 8.0% -2.4% Growth in Syringes and Medical Devices 332 354 91 88 ▪ Phasing within the syringes business and continued growth of medical P&D 27.4% 24.8% devices compensated for
Slide 14: Moulded Glass Powerhouse – Capex Projects Underway
Moulded Glass Powerhouse – Capex Projects Underway Q2 2025 in detail EURm Q2 20241 Q2 2025 Organic YoY% Revenue 185 167 -9.3% Adj. EBITDA margin ~19% ~18% -- Net capex ~€21m ~€27m -- Q2 2025 revenue split by customer industries Cosmetics Food & Beverages Pharma 1 2024 figures on pro forma basis 14 1
Slide 15: Reconciliation Q2 2025
Reconciliation Q2 2025 Reported and adjusted financials Q2 2025 Q2 2024 Org. growth YoY In EURm Reported Adjustment Adjusted Adjusted Adjusted Revenues 600.7 600.7 502.4 1.9% EBITDA 117.6 1.3 118.9 107.3 -4.1% Depreciation & Amortization -66.9 16.5 -50.4 -37.9 EBIT 50.7 17.8 68.5 69.4 Financial Resu
Slide 16: Q2 2025 – Positive Free Cash Flow Development
Q2 2025 – Positive Free Cash Flow Development Cash flow and net financial debt In EURm Q2 2025 Q2 2024 Adjusted EBITDA 118.9 107.3 Adjustments -1.3 -4.7 EBITDA 117.6 102.7 Change in net working capital -15.3 -49.6 Net interest paid -25.1 -13.8 Net taxes paid -10.2 -9.9 Other -5.0 -21.5 Cash flow fro
Slide 17: Financing as of May 30, 2025
Financing as of May 30, 2025 Net financial debt & adjusted EBITDA leverage Net Financial Debt Maturity Profile (ProForma incl. Bormioli Bridge) in EURm In EURm Q2 2025 Q2 2024 982 Revolving credit facilities1 72 305 7364 Bridge loan 780 n.a. 725 Promissory loans 1,208 792 Local borrowings2 60 33 339
Slide 18: Outlook
Outlook Dietmar Siemssen (CEO)
Slide 19: Guidance Gerresheimer Group (including Bormioli)
Guidance Gerresheimer Group (including Bormioli) FY 2025 and New Mid-Term Guidance (organic; group level) Revenue Adjusted EBITDA Adj. EPS2 0-2% ~20% LDD% FY 2025 Growth Margin Decline1 6-9% 23-25% ≥10% Mid-term Growth Margin Growth (New) 1 LDD% Decline = Low Double Digit Decline 2 Currency-adjusted
Slide 20: Drivers towards 6-9% Mid-Term Revenue Growth
Drivers towards 6-9% Mid-Term Revenue Growth Revenues 2025E Solid Base Growth Medical Devices for Biologics High Value Solutions Mid-Term Revenue Unique and broad systems and solutions portfolio providing high value to customers and sustainable long-term growth 20 10-Jul-2025 Gerresheimer AG - Q2 20
Slide 21: Appendix
gerresheimer
Slide 22: Financial Calendar
Financial Calendar Publication 1st Quarter 2026 Results Publication FY 2025 Results Publication 3rd Quarter 2025 Results April 2026 February 2026 Oct 10th, 2025 22 10-Jul-2025 Gerresheimer AG - Q2 2025 Results Presentation
Slide 23: Q2 2025 – Revenue & Organic Growth Reconciliation
Q2 2025 – Revenue & Organic Growth Reconciliation in EURm organic growth +1.9% -13.6 609.3 26.7 -0.1 -1.6 597.9 -8.7 600.7 -5.1% 8.0% 93.9 502.4 1.7 Revenue FX Bormioli Revenue Q2 P&D PPG GAT HQ, Cons. Revenue Q2 FX Revenue Q2 2024 2024 (Pro 2025 (organic) Q2 2025 Forma; organic) 23 10-Jul-2025 Gerr
Slide 24: H1 2025 – Revenue & Organic Growth Reconciliation
H1 2025 – Revenue & Organic Growth Reconciliation in EURm organic growth -2.1% 1,153.8 16.7 -39.4 1,129.1 0.0 -2.1 1,120.7 2.6% -8.4 -7.6% 180.9 968.5 4.4 Revenue FX Bormioli Revenue H1 P&D PPG GAT HQ, Cons. Revenue H1 FX Revenue H1 2024 2024 (Pro 2025 (organic) H1 2025 Forma; organic) 24 10-Jul-202
Slide 25: Q2 2025 – Adj. EBITDA & Organic Growth Reconciliation
Q2 2025 – Adj. EBITDA & Organic Growth Reconciliation in EURm organic growth -4.1% 17.2 126.4 margin -2.1 -0.5 -0.1 -2.4 121.2 -2.2 -2.4% -1.1% 119.0 21.1% 1.8 19.9% 107.3 Adj. EBITDA FX Bormioli Adj. EBITDA Q2 P&D PPG GAT HQ, Cons. Adj. EBITDA Q2 FX Adj. EBITDA Q2 2024 2024 (Pro 2025 (organic) Q2 2
Slide 26: H1 2025 – Adj. EBITDA & Organic Growth Reconciliation
H1 2025 – Adj. EBITDA & Organic Growth Reconciliation in EURm organic growth -6.4% 35.1 227.2 margin -10.4 -3.0 0.5 212.6 -2.2 -1.8 210.4 19.7% -6.4% -3.3% 3.9 18.8% 188.2 Adj. EBITDA FX Bormioli Adj. EBITDA H1 P&D PPG GAT HQ, Cons. Adj. EBITDA H1 FX Adj. EBITDA H1 2024 2024 (Pro 2025 (organic) H1 2
Slide 27: Reconciliation H1 2024
Reconciliation H1 2024 Reported and Adjusted Financials H1 2025 H1 2024 Org. growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 1,120.7 1,120.7 968.5 -2.1% EBITDA 199.6 10.8 210.4 188.2 -6.4% Depreciation & Amortization -133.8 33.6 -100.2 -74.7 EBIT 65.8 44.4 110.2 113.6 Fi
Slide 28: H1 2025 – Free Cash Flow Development
H1 2025 – Free Cash Flow Development Cash flow and net financial debt In EURm H1 2025 H1 2024 Adjusted EBITDA 210.4 188.2 Adjustments -10.8 -7.2 EBITDA 199.6 181.0 Change in net working capital -77.8 -73.9 Net interest paid -32.6 -20.0 Net taxes paid -16.8 -16.1 Other -38.2 -35.8 Cash flow from oper
Slide 29: Pro Forma Revenues and adj. EBITDA 2024
Pro Forma Revenues and adj. EBITDA 2024 Gerresheimer including Bormioli Pharma; EURm Umsatz Q1 24 Q2 24 Q3 24 Q4 24 Full Year 2024 Plastics & Devices 304.0 332.1 321.5 366.3 1,323.9 Primary Packaging Glass 250.3 263.6 259.3 294.1 1,067.3 Advanced Technologies 0.6 2.2 1.4 2.3 6.5 Other/Consolidation
Slide 30: innovating for a better life
innovating for a better life